Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
EXCALIBER-RRMM phase 3 of iberdomide/dara/dex vs dara/bortez/dex shows (median follow-up 15.7 mos) MRD- CR in 85 (41%) vs. 44 (21%); grade 3-4 AEs in 187 (92%) vs 143 (70%), neutropenia (84% vs 11%) & infxn (39% vs 22%).”
Title: Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
Authors: Sagar Lonial, Meletios A. Dimopoulos, Maria Gavriatopoulou, Kihyun Kim, Chang-Ki Min, Albert Oriol, Catarina Campos Costa Moreira, Hang Quach, Lugui Qiu, Zhongjun Xia, Fredrik Schjesvold, Ignacio Casas-Avilés, Yan Xu, Vania Hungria, Güldane C. Seval, Baijun Fang, Charalampia Kyriakou, Henry Miles Prince, Junling Zhuang, Hsin-Chen Lin, María-Victoria Mateos, Ivan Špička, Angelo Maiolino, Filiz Vural, Supratik Basu, Dominik Dytfeld, Chengcheng Fu, Phoebe Joy Ho, Nisha Joseph, Michael Low, Ludek Pour, Saulius Girnius, Jesús G. Berdeja, Paula Rodríguez Otero, Yiming Cheng, Michael Amatangelo, Sarah Hersey, Christian Kazanecki, Marija Bosilkovska Weisskopf, Margee J. Kyada, Patricia C. Abad, Shuyu Chu, Juliane Morando, Paulo Maciag, Paul G. Richardson, Niels W.C.J. van de Donk
You can read the full article on The Lancet Oncology.
You can find other articles featuring Robert Orlowski on OncoDaily.
